In the latest close session, Humacyte, Inc. (HUMA) was up +1.28% at $0.41. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.05%.
Coming into today, shares of the company had lost 30.34% in the past month. In that same time, the Medical sector gained 3.5%, while the S&P 500 gained 0.97%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.09, signifying a 35.71% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.4 per share and a revenue of $4.05 million, signifying shifts of -53.85% and +98.48%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humacyte, Inc. (HUMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).